Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02294630 · ClinicalTrials.gov registry record · Phase 1
Aerosolized Surfactant in Neonatal RDS
A Phase 1 study of Respiratory Distress Syndrome, Newborn, sponsored by Sood, Beena G., MD, MS.
- Completed
- Registry status
- Phase 1
- Development phase
- 159
- Enrollment target
- 1
- Study location
NCT02294630 is a Phase 1 study of Respiratory Distress Syndrome, Newborn that has completed, run by Sood, Beena G., MD, MS. The registered enrollment target is 159 participants, below the 188-participant average among 8 other Respiratory Distress Syndrome, Newborn trials with a reported enrollment target (15% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02294630, a Phase 1 study of Respiratory Distress Syndrome, Newborn, has completed, sponsored by Sood, Beena G., MD, MS.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 159 participants
- Enrollment target
- 1
- Study location
Study Summary
Respiratory distress syndrome (RDS), caused by surfactant deficiency, is the leading cause of mortality and morbidity in preterm infants. Intratracheal instillation, the only approved means of surfactant delivery, requires endotracheal intubation and mechanical ventilation with their attendant risks. Interventions that decrease need for intubation and mechanical ventilation like noninvasive ventilation (NIV) including nasal continuous positive airway pressure, high flow nasal cannula or nasal intermittent mandatory ventilation are increasingly being used for initial respiratory support in preterm neonates with RDS to improve outcomes. Aerosolized surfactant delivered during NIV is an innovative and promising concept for the treatment of RDS - retaining the advantages of early surfactant with alveolar recruitment while obviating the risks of intubation and mechanical ventilation. The investigators overall hypothesis is that treatment of RDS with aerosolized surfactant in preterm infants undergoing NIV is safe and feasible and will result in short-term improvement in oxygenation and ventilation. The objective of this proposal is to perform a single-center unblinded Phase II randomized clinical trial of aerosolized surfactant for the treatment of RDS in preterm neonates undergoing NIV. Funding Source - FDA-OOPD.
Conditions Studied
Interventions
- DRUG Surfactant
Study Locations (1)
Michigan
- Hutzel Women's Hospital - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2014-12 |
| Est. Completion | 2020-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02294630
The ClinicalTrials.gov registry entry for NCT02294630 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 188-participant average among 8 other Respiratory Distress Syndrome, Newborn trials with a reported enrollment target (15% lower). The listed sponsor is Sood, Beena G., MD, MS, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Respiratory Distress Syndrome, Newborn appearing as the primary indexed condition, and to 1 intervention - of which Surfactant is the first listed.
NCT02294630 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT02294630 about?
NCT02294630 is a clinical study titled "Aerosolized Surfactant in Neonatal RDS". Respiratory distress syndrome (RDS), caused by surfactant deficiency, is the leading cause of mortality and morbidity in preterm infants. Intratracheal instillation, the only approved means of surfactant delivery, requires endotracheal intubation and mechanical ventilation with their attendant risks...
What is the current status of trial NCT02294630?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 159 participants. The study started on 2014-12. Estimated completion is 2020-07.
What conditions does trial NCT02294630 study?
This clinical trial studies the following conditions: Respiratory Distress Syndrome, Newborn.
What interventions are being tested in trial NCT02294630?
The interventions under investigation include: Surfactant (DRUG).
Who is sponsoring clinical trial NCT02294630?
This trial is sponsored by Sood, Beena G., MD, MS, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02294630 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Distress Syndrome, Newborn
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Predicting the Need for Prolonged Respiratory Support in Neonates Delivered in a Lower-Level NICU Setting
RECRUITING
-
Echography-guided Surfactant THERapy (ESTHER) For Preterm Infants With Respiratory Failure
RECRUITING · NA
-
Prophylactic Minimally Invasive Surfactant Evaluation
RECRUITING · Phase 4
-
Pulmonary Function Using Non-invasive Forced Oscillometry
ACTIVE NOT RECRUITING · NA
-
ETCare: Safety and Preliminary Efficacy Trial
COMPLETED · Early Phase 1
-
Work of Breathing During Non-invasive Ventilation in Premature Neonates
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.